{"id":13485,"date":"2011-01-11T06:35:47","date_gmt":"2011-01-11T11:35:47","guid":{"rendered":"http:\/\/asweetlife.org\/?p=13485"},"modified":"2015-12-28T08:12:08","modified_gmt":"2015-12-28T13:12:08","slug":"biocon-oral-insulin-shows-promise-in-type-2-diabetes-patients","status":"publish","type":"post","link":"https:\/\/asweetlife.org\/?p=13485","title":{"rendered":"Biocon Oral Insulin Shows Promise in Type 2 Diabetes Patients"},"content":{"rendered":"<div dir=\"ltr\">\n<div style=\"text-align: justify;\"><a href=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/01\/Biocon-logo.jpg\" rel=\"mfp\"><img decoding=\"async\" class=\"alignleft size-full wp-image-13487 lazyload\" title=\"Biocon logo\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" data-src=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/01\/Biocon-logo.jpg\" alt=\"\" width=\"146\" height=\"85\" \/><\/a>Biocon Ltd., India&#8217;s largest biotechnology company, released preliminary data from a recently concluded clinical study conducted in India, on IN-105, its novel oral insulin candidate for the treatment of diabetes.<\/div>\n<p style=\"text-align: justify;\">The study included 264 patients poorly controlled on metformin, who were randomly chosen receive either IN-105 or placebo. The patients in both arms of the study were allowed to continue taking metformin as background therapy.<\/p>\n<p style=\"text-align: justify;\">Initial data analysis showed that IN-105 did not meet its primary end point of lowering HbA1c levels by 0.7% compared to placebo, although an unexpectedly high placebo response was also observed. The reduction in pre-meal glucose levels in patients receiving placebo strongly suggests behavioral modification which may have confounded the primary endpoint outcome.<\/p>\n<div style=\"text-align: justify;\">\n<p>Multiple secondary endpoints on both efficacy and safety were met, further strengthening the emerging profile of IN-105. Most notably on efficacy, the IN-105 patient arm demonstrated a statistically significant reduction in post meal glucose levels compared to placebo throughout the duration of the study.<\/p>\n<p style=\"text-align: justify;\">Source: <a href=\"http:\/\/www.biocon.com\/\" target=\"_blank\">http:\/\/www.biocon.com\/<\/a><\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Biocon Ltd., India&#8217;s largest biotechnology company, released preliminary data from a recently concluded clinical study conducted in India, on IN-105, its novel oral insulin candidate for the treatment of diabetes.<br \/>\nThe study included 264 patients poorly controlled on metformin, who were randomly chosen receive either IN-105 or placebo&#8230;<\/p>\n","protected":false},"author":131,"featured_media":13487,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1441],"tags":[1029,311],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.9 (Yoast SEO v22.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Biocon Oral Insulin Shows Promise in Type 2 Diabetes Patients<\/title>\n<meta name=\"description\" content=\"Biocon released preliminary data from a recently concluded clinical study conducted in India, on IN-105, its novel oral insulin candidate for treatment of diabetes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/asweetlife.org\/?p=13485\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ASweetLife Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/asweetlife.org\/?p=13485\",\"url\":\"https:\/\/asweetlife.org\/?p=13485\",\"name\":\"Biocon Oral Insulin Shows Promise in Type 2 Diabetes Patients\",\"isPartOf\":{\"@id\":\"https:\/\/asweetlife.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/asweetlife.org\/?p=13485#primaryimage\"},\"image\":{\"@id\":\"https:\/\/asweetlife.org\/?p=13485#primaryimage\"},\"thumbnailUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/01\/Biocon-logo.jpg\",\"datePublished\":\"2011-01-11T11:35:47+00:00\",\"dateModified\":\"2015-12-28T13:12:08+00:00\",\"author\":{\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\"},\"description\":\"Biocon released preliminary data from a recently concluded clinical study conducted in India, on IN-105, its novel oral insulin candidate for treatment of diabetes.\",\"breadcrumb\":{\"@id\":\"https:\/\/asweetlife.org\/?p=13485#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/asweetlife.org\/?p=13485\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/?p=13485#primaryimage\",\"url\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/01\/Biocon-logo.jpg\",\"contentUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/01\/Biocon-logo.jpg\",\"width\":146,\"height\":85,\"caption\":\"Biocon logo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/asweetlife.org\/?p=13485#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/asweetlife.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biocon Oral Insulin Shows Promise in Type 2 Diabetes Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/asweetlife.org\/#website\",\"url\":\"https:\/\/asweetlife.org\/\",\"name\":\"ASweetLife\",\"description\":\"The Diabetes Magazine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/asweetlife.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\",\"name\":\"ASweetLife Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"caption\":\"ASweetLife Team\"},\"url\":\"https:\/\/asweetlife.org\/?author=131\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biocon Oral Insulin Shows Promise in Type 2 Diabetes Patients","description":"Biocon released preliminary data from a recently concluded clinical study conducted in India, on IN-105, its novel oral insulin candidate for treatment of diabetes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/asweetlife.org\/?p=13485","twitter_misc":{"Written by":"ASweetLife Team","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/asweetlife.org\/?p=13485","url":"https:\/\/asweetlife.org\/?p=13485","name":"Biocon Oral Insulin Shows Promise in Type 2 Diabetes Patients","isPartOf":{"@id":"https:\/\/asweetlife.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/asweetlife.org\/?p=13485#primaryimage"},"image":{"@id":"https:\/\/asweetlife.org\/?p=13485#primaryimage"},"thumbnailUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/01\/Biocon-logo.jpg","datePublished":"2011-01-11T11:35:47+00:00","dateModified":"2015-12-28T13:12:08+00:00","author":{"@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585"},"description":"Biocon released preliminary data from a recently concluded clinical study conducted in India, on IN-105, its novel oral insulin candidate for treatment of diabetes.","breadcrumb":{"@id":"https:\/\/asweetlife.org\/?p=13485#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/asweetlife.org\/?p=13485"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/?p=13485#primaryimage","url":"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/01\/Biocon-logo.jpg","contentUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/01\/Biocon-logo.jpg","width":146,"height":85,"caption":"Biocon logo"},{"@type":"BreadcrumbList","@id":"https:\/\/asweetlife.org\/?p=13485#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/asweetlife.org\/"},{"@type":"ListItem","position":2,"name":"Biocon Oral Insulin Shows Promise in Type 2 Diabetes Patients"}]},{"@type":"WebSite","@id":"https:\/\/asweetlife.org\/#website","url":"https:\/\/asweetlife.org\/","name":"ASweetLife","description":"The Diabetes Magazine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/asweetlife.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585","name":"ASweetLife Team","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","caption":"ASweetLife Team"},"url":"https:\/\/asweetlife.org\/?author=131"}]}},"_links":{"self":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/13485"}],"collection":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13485"}],"version-history":[{"count":0,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/13485\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/media\/13487"}],"wp:attachment":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13485"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13485"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13485"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}